期刊
PHARMACEUTICALS
卷 3, 期 12, 页码 3581-3593出版社
MDPI
DOI: 10.3390/ph3123581
关键词
artemisinin-naphthoquine combination; ARCO; artemisinin; naphthoquine; Plasmodium falciparum
With the rapidly spreading resistance of Plasmodium falciparum to available non-artemisinin antimalarial drugs, new and novel pharmaceuticals are needed. ARCO (R) is a new generation ACT, one of several artemisinin-based combinations developed in China to counter antimalarial drug resistance. ARCO (R) is a derivative of two independently developed antimalarials, artemisinin and naphthoquine phosphate, which were combined to form the artemisinin-naphthoquine combination. Both artemisinin and naphthoquine drugs have proven to be efficacious, safe and well tolerated as monotherapies. The artemisinin-naphthoquine combination offers a novel advantage over existing ACTs: it can be administered as a single oral dose (or a 1-day treatment). Several therapeutic studies conducted recently indicate that a single oral dose administration of artemisinin-naphthoquine combination is equally effective and safe as the 3-day treatment with artemether-lumefantrine combination and other existing ACTs. This would make ARCO (R) the next generation ACT for the treatment of uncomplicated falciparum malaria.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据